Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects
Authors not listed
Janssen Research & Development, LLC · 2013
Abstract
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-ascending dose JNJ-54861911 which is currently being developed for the treatment of Alzheimer's disease.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Anonymous. (2013). A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects. <em>Janssen Research & Development, LLC</em>. https://clinicaltrials.gov/study/NCT01887535
Vancouver
Anonymous. A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects. Janssen Research & Development, LLC. 2013.
BibTeX
@misc{anon2013ADoubl,
title = {A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects},
author = {Anonymous},
journal = {Janssen Research & Development, LLC},
year = {2013},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Vigil Neuroscience, Inc. 2023
Open access · US-GOV
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927
Asceneuron Pty Ltd. 2021
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Oral ASN51 in Healthy Young Adult and Elderly Subjects and Elderly Subjects With Alzheimer's Disease
Hoffmann-La Roche 2021
Open access · US-GOV
A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease
Denali Therapeutics Inc. 2026
Open access · US-GOV
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease
Kyowa Kirin Co., Ltd. 2017
Open access · US-GOV
A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease
Janssen Research & Development, LLC 2017
Open access · US-GOV